Force Pharma Capital Competitors

New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. Founded in 1977, NEA has more than $35 billion in assets under management as of December 31, 2025, and invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm's long track record of investing includes more than 285 portfolio company public listings and more than 510 mergers and acquisitions. For more information, please visit www.nea.com.

OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

Gryphon Investors is a leading middle-market private investment firm focused on building and growing profitable, market-leading companies in the Business Services, Consumer, Healthcare, Industrial Growth, Software & Technology Solutions & Services sectors. As of June 30, 2025, Gryphon manages $10+ billion from our Flagship, Gryphon Heritage, and Junior Capital Funds. The firm’s highly-differentiated and fully-integrated “Deal-Ops” model combines industry and functional operating expertise across the disciplines of general management, human capital, IT, AI, and finance and accounting.